Streetbeat News

Earnings

CHRS

Coherus BioSciences reported mixed Q3 financial results and lowered its guidance, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:34 pm

ALTO

Alto Ingredients reported mixed Q3 financial results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:33 pm

TMDX

TransMedics reported better-than-expected Q3 sales results and issued FY23 revenue guidance above estimates, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:33 pm

SANM

Sanmina Corporation reported worse-than-expected Q4 financial results, leading to a drop in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:32 pm

HIMS

Hims & Hers reported better-than-expected Q3 sales results and raised its FY23 guidance above estimates. The company also announced a $50 million share repurchase program, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:31 pm

TASK

TaskUs reported better-than-expected Q3 financial results and issued Q4 and FY23 revenue guidance above estimates, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:31 pm

IFF

International Flavors & Fragrances Inc. (IFF) shares are trading higher after the company reported better-than-expected Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:30 pm

AYX

Alteryx reported better-than-expected Q3 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 2:29 pm

CLOV

Clover Health Investments Corp (NASDAQ:CLOV) reported Q3 revenue of $482.07 million, missing the consensus estimate of $494.6 million. Insurance revenues were up 12% YoY to $301.2 million. The company reported an adjusted EBITDA loss of $5.1 million, improved from a loss of $55.5 million YoY. Clover Health revised its 2023 adjusted EBITDA outlook from a loss of $70 million to $120 million to a loss of $55 million to $80 million. The company updated its full-year 2023 insurance revenue outlook from a range of $1.2 to $1.23 billion to a new range of $1.21 to $1.23 billion.

Portfolio Pulse from Adam Eckert

November 07, 2023 | 2:28 pm

INGR

Ingredion Inc reported Q3 FY23 sales growth of 1% YoY to $2.03 billion, missing the analyst consensus estimate of $2.114 billion. The revenue increase was driven by price mix and foreign exchange impacts, partially offset by volume declines. Adjusted EPS of $2.33 beat the consensus estimate of $1.95. The company raised its FY23 adjusted EPS outlook from $8.80 - $9.40 to $9.05 - $9.45 against the consensus of $9.00. INGR shares closed lower by 0.28% at $95.62 on Monday.

Portfolio Pulse from Shivani Kumaresan

November 07, 2023 | 2:25 pm